We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+32.87%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$435M
AUM Growth
+$90.3M
Cap. Flow
+$69M
Cap. Flow %
15.87%
Top 10 Hldgs %
46.41%
Holding
58
New
21
Increased
13
Reduced
6
Closed
12

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$16.9M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$15.1M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.7M
4
PTCT icon
PTC Therapeutics
PTCT
+$14M
5
PRTA icon
Prothena Corp
PRTA
+$11.3M

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$22M
2
CELG
Celgene Corp
CELG
+$20.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$14.4M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 73.43%
2 Miscellaneous 26.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$38.6M 8.88%
1,200,000
+106,200
+10% +$3.92M
CBST
2
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$21.9M 5.05%
300,000
-100,000
-25% -$7.46M
PBYI icon
3
Puma Biotechnology
PBYI
$477M
$21.6M 4.97%
207,500
+7,500
+4% +$882K
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12.5B
$20.5M 4.71%
300,000
+200,000
+200% +$14.7M
RCPT
5
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$18.9M 4.34%
450,000
+100,000
+29% +$4.3M
DYAX
6
DELISTED
DYAX CORPORATION
DYAX
$18M 4.13%
2,000,000
-850,000
-30% -$7.73M
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$16.5M 3.79%
+50,000
New +$16.9M
ARWR icon
8
Arrowhead Research
ARWR
$9.55B
$16.4M 3.78%
1,000,000
+4,500
+0.5% +$79K
IDIX
9
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$15.1M 3.47%
2,500,000
-425,000
-15% -$2.96M
PTCT icon
10
PTC Therapeutics
PTCT
$5.63B
$14.4M 3.31%
550,000
+521,200
+1,810% +$14M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.8B
$13.9M 3.19%
+100,000
New +$15.1M
PRTA icon
12
Prothena Corp
PRTA
$428M
$13.4M 3.08%
+350,000
New +$11.3M
DXCM icon
13
DexCom
DXCM
$33.2B
$12.4M 2.85%
1,200,000
– –
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.11B
$12.4M 2.84%
1,168,000
+900,000
+336% +$9.6M
MRK icon
15
Merck
MRK
$356B
$11.4M 2.61%
+209,600
New +$10.9M
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.8M 2.49%
600,000
+433,800
+261% +$8.36M
TLPH icon
17
Talphera
TLPH
$61.8M
$9.01M 2.07%
37,500
– –
SRNE
18
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$8.97M 2.06%
+700,000
New +$7.75M
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$8.84M 2.03%
300,000
– –
ALKS icon
20
Alkermes
ALKS
$7.72B
$8.82M 2.03%
+200,000
New +$9.52M
KPTI icon
21
Karyopharm Therapeutics
KPTI
$37.7M
$8.65M 1.99%
18,667
+12,000
+180% +$6.08M
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$8.31M 1.91%
120,000
+700
+0.6% +$51.4K
NSTG
23
DELISTED
NanoString Technologies, Inc.
NSTG
$8.26M 1.9%
+400,000
New +$7.62M
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$8.22M 1.89%
1,750,000
– –
CBIO
25
Crescent Biopharma
CBIO
$660M
$7.67M 1.76%
+4,694
New +$5.68M
1
2 3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Cormorant Asset Management held 58 positions worth $435M, up 26% from $345M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $69M of net new capital in Q1 2014, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 65% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.5M trimmed.

  • Cormorant Asset Management's largest Q1 2014 buy was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.
  • Cormorant Asset Management added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $14.7M increase.
  • Cormorant Asset Management's biggest Q1 2014 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.5M.
  • Cormorant Asset Management fully exited Keryx Biopharmaceuticals Inc in Q1 2014, selling an estimated $22M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $435M portfolio in Q1 2014.
  • Cormorant Asset Management opened 21 new positions and closed 12 in Q1 2014.
  • Cormorant Asset Management's portfolio value rose 26% quarter-over-quarter to $435M.

Based on Cormorant Asset Management's 13F filing for Q1 2014, filed 15 May 2014.